1 / 7

CINVForum W eb -symposium dedicated to chemotherapy induced nausea and vomiting in lung cancer patients

CINVForum W eb -symposium dedicated to chemotherapy induced nausea and vomiting in lung cancer patients. Survey on CINV – R esults Base: 168 registered physicians. Prevention of CINV – Risk factors. Base: 168.

mika
Télécharger la présentation

CINVForum W eb -symposium dedicated to chemotherapy induced nausea and vomiting in lung cancer patients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CINVForumWeb-symposium dedicated to chemotherapy induced nausea and vomiting in lung cancer patients Survey on CINV – Results Base: 168 registeredphysicians

  2. Preventionof CINV – Riskfactors Base: 168 Q1. Do you consider the patient-related risk factors (e.g. gender, age, CINV history etc.)? Q2. Do you evaluate the treatment-related risk factors (e.g. chemotherapy emetogenicity, single or multiple day regimens, chemotherapy agents combination, doses etc.)?

  3. Prevention of CINV – International guidelines Base: 168 Q3. Do you take into consideration the international antiemetic guidelines (NCCN, ASCO, MASCC/ESMO)? Q3.1. If yes, which international antiemetic guidelines do you refer to?

  4. Preventionof CINV – Chemotherapy treatment Base: 168 Q4. Did your patients have to postpone chemotherapy treatment due to CINV?

  5. Preventionof CINV – CINV monitoring Base: 168 Q5. Do you regularly monitor CINV episodes in your patients? Q5.2. If yes, how do you monitor CINV episodes? Q5.1. If yes, Who does receive the patients' feedback?

  6. Preventionof CINV – Patients’ feedback Base: 168 Q6. If you or the nurse doesn't regularly monitor CINV, do your patients voluntarily complain about Vomiting? Q7. If you or the nurse doesn't regularly monitor CINV, do your patients voluntarily complain about Nausea?

  7. Preventionof CINV – MAT Tool Base: 168 Q8. Do you know/use the MASCC Antiemesis Tool (MAT), now available also as App for iPhone/iPad, developed by Multinational Association of Supportive Care in Cancer (MASCC)?

More Related